Cancer cells are able to elaborate enzymatic mechanisms allowing tumors to resist or escape imune rejection.
Among the enzymes involved, indoleamine 2,3-dioxygenase (IDO), an intracellular enzyme that initiates the first and
rate-limiting step of tryptophan breakdown along the kynurenine pathway, has emerged as a promising molecular target
for the development of new immunotherapeutic anticancer agents. This review summarizes the synthesis and IDO
activities of the different classes of marine and other inhibitors reported so far.
Keywords: Indoleamine 2, 3-dioxygenase, IDO inhibitors, marine natural compounds.
Rights & PermissionsPrintExport